Compare FIHL & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FIHL | RCKT |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 340.9M |
| IPO Year | 2023 | N/A |
| Metric | FIHL | RCKT |
|---|---|---|
| Price | $19.48 | $3.48 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 14 |
| Target Price | $21.14 | ★ $29.12 |
| AVG Volume (30 Days) | 611.3K | ★ 1.9M |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.08% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,573,400,000.00 | N/A |
| Revenue This Year | $9.79 | N/A |
| Revenue Next Year | $9.45 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.89 | N/A |
| 52 Week Low | $14.17 | $2.19 |
| 52 Week High | $19.83 | $13.35 |
| Indicator | FIHL | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 59.83 | 55.01 |
| Support Level | $19.43 | $3.19 |
| Resistance Level | $19.72 | $3.60 |
| Average True Range (ATR) | 0.41 | 0.19 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 82.38 | 70.65 |
Fidelis Insurance Holdings Ltd is a specialty insurer that leverages strategic partnerships to offer tailored insurance solutions. The company classifies its business into two segments, Insurance and Reinsurance. A majority of its revenue is generated from the Insurance segment, which comprises a portfolio of property, marine, aviation and aerospace, political risk, violence and terror, energy, cyber, and other insurance risks. The Reinsurance segment consists of an actively managed property reinsurance book, providing reinsurance and a limited amount of retrocession coverage across the world on a proportional or excess-of-loss basis. Geographically, the company derives its key revenue from the United Kingdom, followed by Bermuda and the Republic of Ireland.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.